Insights

AstraZeneca vaccine approved for use in Australia, CSL (ASX:CSL) share price up

The CSL Limited (ASX:CSL) share price rose 2% after the AstraZeneca – Oxford University COVID-19 vaccine was approved in Australia.
The post AstraZeneca vaccine approved for use in Australia, CSL (ASX:CSL) share price up appeared first on The Motley Fool Australia. –

covid vaccine stocks represented by row of vials labelled covid vaccine

The CSL Limited (ASX: CSL) share price climbed 2% today after the AstraZeneca – Oxford University COVID-19 vaccine was approved for use in Australia.

According to reporting by the Australian Financial Review, the provisional approval will mean that adults who are 18 or older will be able to take two doses of the drug, between four to twelve weeks apart.

The Australian federal government has ordered almost 54 million doses of the vaccine, with CSL to start manufacturing within the country from the end of next month. CSL has been tasked with manufacturing 50 million doses. 

One of the main benefits of the Oxford University – AstraZeneca COVID-19 vaccine is that it can be held in normal refrigerators. The Pfizer COVID-19 vaccine needs to be stored at -70C.

Some of the first Australians to receive the vaccine will be border workers, health workers involved in the fight against COVID-19, and people who are involved in aged care settings.

What is CSL’s involvement in the COVID-19 vaccine?

In regards to the COVID-19 vaccine, CSL announced back in September 2020 that it had signed an agreement with the Australian federal government.

CSL will manufacture the COVID-19 vaccine from its Australian facilities, as well as manufacturing the company’s vital core therapies.

The Australian government has provided funding to support CSL’s readiness to manufacture the Oxford University – AstraZeneca vaccine, which has expanded Australia’s on-shore vaccine manufacturing capabilities.

The funding is being used to establish at-risk components required to produce the commercial manufacture of the recombinant vector-based COVID-19 vaccine, including funding for specialised equipment, recruitment training and redeployment of personnel and retooling and reconfiguration of existing manufacturing facilities to ‘good manufacturing practice’ standards.

At the time of the announcement of the deal with the federal government, CSL CEO and managing director Paul Perreault said:

“Acknowledging that CSL is the only company in Australia with manufacturing facilities capable of producing this vaccine, we thank the Australian government for their support, ensuring Australia has access to onshore COVID-19 vaccine production and supply. Our facilities will require modifications in order to fulfil the compliance requirements for working with vector-based vaccines, as well as the addition of skilled personnel and further capital investment.”

Mr Perreault also spoke of the company’s prior involvement in manufacturing vaccines: “CSL’s history is linked with a commitment to Australia’s public health needs. In 1918 we produced a vaccine for the Spanish influenza pandemic, in 2009 we developed a vaccine for the swine flu pandemic, and now we are incredibly proud to use our skills, technology and facilities to help ensure Australia – and the world – can access a COVID-19 vaccine.”

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post AstraZeneca vaccine approved for use in Australia, CSL (ASX:CSL) share price up appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!